Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 1
2014 1
2015 1
2017 1
2019 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Long-term progression of clinician-reported and gait performance outcomes in hereditary spastic paraplegias.
Cubillos Arcila DM, Dariva Machado G, Martins VF, Leotti VB, Schüle R, Peyré-Tartaruga LA, Saute JAM. Cubillos Arcila DM, et al. Front Neurosci. 2023 Sep 22;17:1226479. doi: 10.3389/fnins.2023.1226479. eCollection 2023. Front Neurosci. 2023. PMID: 37811319 Free PMC article.
INTRODUCTION: Hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative diseases in which little is known about the most appropriate clinical outcome assessments (COAs) to capture disease progression. ...The progression slopes of CO …
INTRODUCTION: Hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative diseases in which little is …
Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial.
Diniz de Lima F, Faber I, Servelhere KR, Bittar MFR, Martinez ARM, Piovesana LG, Martins MP, Martins CR Jr, Benaglia T, de Sá Carvalho B, Nucci A, França MC Jr. Diniz de Lima F, et al. Mov Disord. 2021 Jul;36(7):1654-1663. doi: 10.1002/mds.28523. Epub 2021 Feb 17. Mov Disord. 2021. PMID: 33595142 Clinical Trial.
BACKGROUND: Hereditary spastic paraplegia presents spasticity as the main clinical manifestation, reducing gait quality and producing incapacity. ...The objective of the current study was to evaluate the efficacy and safety of BoNT-A in patients with …
BACKGROUND: Hereditary spastic paraplegia presents spasticity as the main clinical manifestation, reducing gait …
Improving gait adaptability in patients with hereditary spastic paraplegia (Move-HSP): study protocol for a randomized controlled trial.
van de Venis L, van de Warrenburg BPC, Weerdesteyn V, van Lith BJH, Geurts ACH, Nonnekes J. van de Venis L, et al. Trials. 2021 Jan 7;22(1):32. doi: 10.1186/s13063-020-04932-9. Trials. 2021. PMID: 33413555 Free PMC article.
BACKGROUND: People with hereditary spastic paraplegia (HSP) experience difficulties adapting their gait to meet environmental demands, a skill required for safe and independent ambulation. ...In addition, this study aims to identify key determinants of C-Mill …
BACKGROUND: People with hereditary spastic paraplegia (HSP) experience difficulties adapting their gait to meet environ …
Management of Hereditary Spastic Paraplegia: A Systematic Review of the Literature.
Bellofatto M, De Michele G, Iovino A, Filla A, Santorelli FM. Bellofatto M, et al. Front Neurol. 2019 Jan 22;10:3. doi: 10.3389/fneur.2019.00003. eCollection 2019. Front Neurol. 2019. PMID: 30723448 Free PMC article.
The term hereditary spastic paraplegia (HSP) embraces a clinically and genetically heterogeneous group of neurodegenerative diseases characterized by progressive spasticity and weakness of the lower limbs. ...Disagreements were resolved by discussion. The 27 …
The term hereditary spastic paraplegia (HSP) embraces a clinically and genetically heterogeneous group of neurodegenera …
Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial.
Schöls L, Rattay TW, Martus P, Meisner C, Baets J, Fischer I, Jägle C, Fraidakis MJ, Martinuzzi A, Saute JA, Scarlato M, Antenora A, Stendel C, Höflinger P, Lourenco CM, Abreu L, Smets K, Paucar M, Deconinck T, Bis DM, Wiethoff S, Bauer P, Arnoldi A, Marques W, Jardim LB, Hauser S, Criscuolo C, Filla A, Züchner S, Bassi MT, Klopstock T, De Jonghe P, Björkhem I, Schüle R. Schöls L, et al. Brain. 2017 Dec 1;140(12):3112-3127. doi: 10.1093/brain/awx273. Brain. 2017. PMID: 29126212 Free PMC article. Clinical Trial.
Spastic paraplegia type 5 (SPG5) is a rare subtype of hereditary spastic paraplegia, a highly heterogeneous group of neurodegenerative disorders defined by progressive neurodegeneration of the corticospinal tract motor neurons. ...We thus demons
Spastic paraplegia type 5 (SPG5) is a rare subtype of hereditary spastic paraplegia, a highly heterogeneo
Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia.
Margetis K, Korfias S, Boutos N, Gatzonis S, Themistocleous M, Siatouni A, Dalivigka Z, Flaskas T, Stranjalis G, Boviatsis E, Sakas D. Margetis K, et al. Clin Neurol Neurosurg. 2014 Aug;123:142-5. doi: 10.1016/j.clineuro.2014.05.024. Epub 2014 Jun 4. Clin Neurol Neurosurg. 2014. PMID: 24973568 Clinical Trial.
OBJECTIVE: We study the effectiveness and safety of intrathecal baclofen therapy for the treatment of spasticity and gait improvement in patients suffering from hereditary spastic paraplegia. METHODS: Sixteen patients diagnosed with hereditary spast
OBJECTIVE: We study the effectiveness and safety of intrathecal baclofen therapy for the treatment of spasticity and gait improvement in pat …
Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases.
Hecht MJ, Stolze H, Auf dem Brinke M, Giess R, Treig T, Winterholler M, Wissel J; German Spasticity Education Group. Hecht MJ, et al. Mov Disord. 2008 Jan 30;23(2):228-33. doi: 10.1002/mds.21809. Mov Disord. 2008. PMID: 17999430
Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. ...We report the effect of BoNT-A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the mod
Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. ...We report the effect of BoNT-A i
Ultrasound-guided botulinum toxin injection technique for the iliopsoas muscle.
Westhoff B, Seller K, Wild A, Jaeger M, Krauspe R. Westhoff B, et al. Dev Med Child Neurol. 2003 Dec;45(12):829-32. doi: 10.1017/s0012162203001531. Dev Med Child Neurol. 2003. PMID: 14667075 Free article. Clinical Trial.
Indications were functional iliopsoas shortening due to cerebral palsy (17 hips), hereditary spastic paraplegia (four hips), and Perthes disease (five hips). ...The main indications for BTX-A injections in the iliopsoas muscle are dynamic hip flexion d …
Indications were functional iliopsoas shortening due to cerebral palsy (17 hips), hereditary spastic paraplegia